Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408881 | 1.00 | IDO1 (0.42) | IDO1MAOBCA1CA2APP | |
| SCHEMBL12361734 | 0.84 | AGXT (0.44) | MAOBCA1CA2HPGDHTT | |
| SCHEMBL1013889 | 0.82 | IDO1 (0.42) | IDO1MAOBCA1CA2APP | |
| SCHEMBL556155 | 0.82 | IDO1 (0.42) | IDO1MAOBCA1CA2APP | |
| SCHEMBL149042 | 0.81 | CA1 (0.53) | CA1CA2KDM4EHTTCA7 | |
| SCHEMBL4909693 | 0.81 | CA1 (0.53) | CA1CA2KDM4EHTTCA7 | |
| SCHEMBL4545487 | 0.81 | CA1 (0.53) | CA1CA2KDM4EHTTCA7 | |
| SCHEMBL2405469 | 0.81 | IDO1 (0.45) | IDO1MAOBCA1CA2APP | |
| SCHEMBL2405472 | 0.81 | IDO1 (0.45) | IDO1MAOBCA1CA2APP | |
| SCHEMBL18843235 | 0.81 | CA1 (0.59) | IDO1CA1CA2APPHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2212317-A1 | 4,4-DISUBSTITUTED PIPERIDINES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009053452-A1 | 4,4-DISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | REN, AGTR2, AVPR2 | IDO1 3753/4885MAOB 891/4885CA1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.